Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech | Frank Vinluan | 06/02/20 | Seattle |
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More | Frank Vinluan | 02/01/19 | National |
Aduro Biotech Slashes Staff 37%, Turns Focus to Lead Cancer Drugs | Frank Vinluan | 01/30/19 | San Francisco |
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More | Frank Vinluan | 10/05/18 | National |
Tempest Therapeutics Debuts with $70M to Bring Cancer Drugs to Clinic | Frank Vinluan | 03/28/18 | San Francisco |
Bio Roundup: Tax Cuts, a Funding Rush, Hemophilia Questions & More | Alex Lash | 12/15/17 | National |
Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy | Frank Vinluan | 02/27/17 | New York |
Led by Former Lilly Exec, Apexian Out to Tackle Pancreatic Cancer | Frank Vinluan | 11/16/16 | Indiana |
Safety Issue Triggers Partial FDA Hold for Aduro Bio | Ben Fidler | 10/24/16 | San Francisco |
Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches | Alex Lash | 09/07/16 | National |
The Biotech Roundup: Immunotherapy Ups And Downs, Gene Deals & More | Alex Lash | 05/20/16 | National |
Aduro Takes Hit On Pancreatic Cancer Trial Miss, But Shares Rebound | Alex Lash | 05/16/16 | San Francisco |
Aduro Lands New Berkeley Life Sciences Digs, with Room to Grow | Bernadette Tansey | 09/18/15 | San Francisco |
West Coast Biotech Roundup: CRISPR, Doudna, Aduro, Amgen, NEA & More | Alex Lash | 04/16/15 | San Francisco |
Aduro BioTech Obtains $119,000,000 New Funding | VentureDeal | 04/15/15 | San Francisco |
Pop That Bubble: 5 Reasons Biotech Needs A Different Metaphor | Alex Lash | 04/14/15 | National |
West Coast Biotech Roundup: Auspex, Hyperion, NuVasive, & More | Bruce V. Bigelow | 04/02/15 | San Diego |
Novartis Bets $250M-Plus on Aduro’s Immuno-Oncology Work | Bernadette Tansey | 03/30/15 | San Francisco |
West Coast Biotech Roundup: Apple, 23andMe, Amgen, Acadia & More | Alex Lash | 03/13/15 | San Francisco |
West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More | Alex Lash | 01/08/15 | San Francisco |
One Week Into The New Year, Five Biotechs Reel in $220M Venture Cash | Alex Lash | 01/08/15 | National |
West Coast Biotech Roundup: IPOs, Gilead, Sofinnova, & Denouements | Bruce V. Bigelow | 07/25/14 | San Diego |
West Coast Biotech Roundup: Burrill, Topol, Aduro, Receptos, & More | Alex Lash | 06/19/14 | San Francisco |
With J&J Deals, Aduro’s Cancer Vaccines Have New Chance To Prove Worth | Bernadette Tansey | 06/18/14 | San Francisco |
Aduro BioTech Garners $55,000,000 Series C Funding Round | VentureDeal | 06/12/14 | San Francisco |
Aduro BioTech Secures $6,500,000 New Financing | VentureDeal | 01/31/13 | San Francisco |